Formycon AG (0W4N.L)

EUR 53.2

(0.95%)

Operating Expenses Summary of Formycon AG

  • Formycon AG's latest annual operating expenses in 2023 was 23.73 Million EUR , down -20.36% from previous year.
  • Formycon AG's latest quarterly operating expenses in 2024 Q2 was 19.89 Million EUR , down 0.0% from previous quarter.
  • Formycon AG reported a annual operating expenses of 29.8 Million EUR in annual operating expenses 2022, up 24.49% from previous year.
  • Formycon AG reported a annual operating expenses of 23.93 Million EUR in annual operating expenses 2021, up 573.84% from previous year.
  • Formycon AG reported a quarterly operating expenses of 12.58 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • Formycon AG reported a quarterly operating expenses of 23.73 Million EUR for 2023 FY, down -20.36% from previous quarter.

Annual Operating Expenses Chart of Formycon AG (2023 - 2009)

Historical Annual Operating Expenses of Formycon AG (2023 - 2009)

Year Operating Expenses Operating Expenses Growth
2023 23.73 Million EUR -20.36%
2022 29.8 Million EUR 24.49%
2021 23.93 Million EUR 573.84%
2020 3.55 Million EUR 9.87%
2019 3.23 Million EUR -72.12%
2018 11.59 Million EUR 18.42%
2017 9.79 Million EUR 19.16%
2016 8.21 Million EUR 9.41%
2015 7.51 Million EUR 29.34%
2014 5.8 Million EUR -11.04%
2013 6.52 Million EUR 159.99%
2012 2.51 Million EUR 89.96%
2011 1.32 Million EUR 24.48%
2010 1.06 Million EUR 464.95%
2009 188 Thousand EUR 0.0%

Peer Operating Expenses Comparison of Formycon AG

Name Operating Expenses Operating Expenses Difference
Boiron SA 317.27 Million EUR 92.52%
Laboratorios Farmaceuticos Rovi, S.A. 263.09 Million EUR 90.979%
Vetoquinol SA 217.11 Million EUR 89.069%
Valneva SE 134.92 Million EUR 82.41%
AB Science S.A. 14.01 Million EUR -69.328%
Nanobiotix S.A. 62.98 Million EUR 62.321%
PHAXIAM Therapeutics S.A. 24.98 Million EUR 5.015%
Vivoryon Therapeutics N.V. 24.69 Million EUR 3.884%
BioSenic S.A. 7.58 Million EUR -212.976%
ABIVAX Société Anonyme 127.37 Million EUR 81.368%